It is important, as nursing home abuse lawyers practicing in the New Jersey and Philadelphia area, to help expose the nursing homes that are not just below average, but that provide a low quality of life for their residents. These below average nursing homes are the ones often responsible for the acts of abuse that patients (our loved ones) must be protected from. The State of New Jersey conducts routine inspections of all nursing homes and long term health care facilities in the state.
The subject of today’s post is a for profit, corporately owned nursing home located in Burlington County, New Jersey. The facility holds 156 long term care beds and was given a below average overall rating by the Official US Government Site for Medicare in its nursing home comparisons.
Marcell Center Fails to Impress Inspectors from Medicare and the State of Jersey
The Marcella Center, located on Rancocas Road in Burlington, had two routine inspections between November 2008 and October 2010. During that time, the facility was cited for 19 separate deficiencies. In the Medicare Nursing Home Compare System, it received an overall rating of 2 out of 5 stars, which is considered below average.
Among Marcella’s numerous citations, one had to do with not giving residents proper treatment to prevent new bed (pressure) sores, or to heal those existing sores. A violation of this magnitude is not something to be ignored or brushed aside, as the improper care of a bed sore can be very dangerous and extremely painful for the patient. During this same time period, 6 complaint inspections were conducted with an additional 5 deficiencies cited. These inspections put the number of citations above the average for the United States and for New Jersey.
Nursing Home Abuse Lawyers in New Jersey and Philadelphia
As always, it is important to do your research before utilizing a particular nursing home, and to continue to monitor its standard of care throughout your loved ones stay. This truly can make the difference between life and death in some patients.
If your loved one is a resident at a nursing home or long term care facility, and you believe the care they are receiving is insufficient, negligent, or abusive, contact the Mininno Law Office for a free case evaluation, or call for a free consultation at (856) 833-0600 in New Jersey, or (215) 567-2380 in Philadelphia.
Recent news demonstrates that not only are DePuy recall lawyers and patients planning for the litigation, but Johnson & Johnson and DePuy have also recognized the potential problem and have taken financial steps to prepare themselves. According to Johnson & Johnson’s fourth quarter earnings report released this past month, the company is taking a $922 million charge related to its potential exposure for the DePuy hip recall. While $922 million may sound like a large sum of money, it may be inadequate to cover the sum of 93,000 potential claimants that will require compensation from Johnson & Johnson.
Medical students at the University researched and reviewed notes written by American neurosurgeon Harvey Cushing. Cushing is considered the “father of modern neurosurgery” and a pioneer of the brain surgery that we know of today. He developed many of the techniques that neurosurgeons still use, dramatically increasing patient survival rates after such invasive and dangerous procedures on the brain.
A 
This for-profit, corporately owned nursing home was cited for a variety of deficiencies from November 2008 through October 2010. The citations were in a wide variety of categories including, among others, nutrition/dietary needs, living environment, and pharmaceutical responsibilities. For example, it indicated that some residents were affected by the fact that the pharmacy made medication errors of more than 5%. These errors are defined as administering the wrong drugs, administering the wrong doses, or administering drugs ate the wrong times. Medication errors can lead to many serious health issues. 
As a 
On the day of her daughter Cassie’s birth, Dr. Lisa Yang and her colleagues administered drugs and forced the kind of birth deemed nearly impossible early on in Heather’s pregnancy. The drugs administered were supposed to assist the uterus in contracting, and eventually the baby would be expelled. However, because of her mother’s condition, and because of Cassie’s size, which the doctors failed to consider, Cassie’s head became stuck. 
For years, the FDA has permitted a regulatory loophole under FDA 510(k) which permits the release of new medical devices like the DePuy hip implant, Zimmer NexGen knee implant, and other medical devices, to be placed onto the market without first receiving a comprehensive review by the FDA. How? Because this loophole permits implant manufacturers, like DePuy, to obtain FDA approval if a medical device manufacturer shows that its device is “substantially equivalent” in safety and effectiveness to another FDA approved device.
Dr. Stephen Serlin was summoned at 5am on February 24th, 1993 to perform an emergency C-section for Marlayna’s mother, Dawn Kineke. He did not arrive at the hospital until 7am, and the procedure didn’t begin until 8:14am. In that time, Marlayna suffered fetal asphyxia from umbilical cord compression within the womb, which caused cerebral palsy and a host of additional developmental issues.
In fact, some hip replacement surgeons have argued that hip implant and joint replacement surgery is one of the most important surgical advances over the last century. Because of its popularity, and potential profitability, hip manufacturers such as DePuy, Johnson & Johnson, Zimmer, and others have been competing to capture this potentially lucrative market. Unfortunately, as has been suggested with DePuy, sometimes manufacturers are in such a rush to roll out a “new and improved” implant device, they fail to properly test whether the hip, knee, or other joint implant is better than those that already existed on the market.